


CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date.			
Typed or Printed Name	Susan M. Alessi		
Signature	<i>Susan Alessi</i>	Date	May 16, 2003
INFORMATION DISCLOSURE STATEMENT Address to: Commissioner for Patents Washington, D.C. 20231 		Attorney Docket	RIGL-011
		First Named Inventor	ANDERSON, DAVID
		Application Number	09/710,058
		Filing Date	November 10, 2000
		Group Art Unit	1639
		Examiner Name	CELSA, BENNETT M.
		Title: "METHODS AND COMPOSITIONS COMPRISING RENILLA GFP"	

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. This is being filed **after** three months of the filing date of this national application or the date of entry of the national stage as set forth in §1.491 in an international application or **after** the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.

A Form PTO-SB/08A listing the references accompanies this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

- ☒ All of the references identified herein are being submitted prior to the final determination on patentability by the Office.
- ☐ All of the references identified herein were cited in an International (PCT) Search Report dated *, in a PCT application corresponding to the above-identified U.S. application. A copy of the Search Report, including an indication of the purported relevance of the cited documents, is enclosed herewith. Copies of the references are submitted herewith.
- ☐ All of the references identified herein were disclosed in parent application Serial No. 60/164,592 and, as such, copies thereof are not included pursuant to the provisions of 37 C.F.R. §1.98(d), except if noted below.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

05/27/2003 HHCHHHH1 00000008 500815 09710058

01 FC:1806 180.00 CH

X Please charge the \$180.00 fee required by 37 C.F.R. §1.97(c) and set forth in 37 C.F.R. 1.17(p) and any additional fees which may be required by this paper or any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21, or to credit any overpayment, to Deposit Account No. 50-0815, order number RIGL-011.


Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: May 16, 2003

By: 

James S. Keddie, Ph.D.
Registration No. 48,920

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/710,058
		Filing Date	November 10, 2000
		First Named Inventor	ANDERSON, DAVID
		Art Unit	1639
Examiner Name	CELSA, BENNETT M.		
Attorney Docket Number	RIGL-011		
Sheet	1	of	4

RECEIVED
MAY 28 2003
TECH CENTER 1600 2900

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
		US- 5.798.441		Aug. 25, 1998	CORMIER et al.	
		US- 5.874.304		Feb. 23, 1999	ZOLOTHKHIN et al.	
		US- 5.925.558		Jul. 20, 1999	TSIEN et al.	
		US- 5.958.713		Sep. 28, 1999	THASTRUP et al.	
		US- 5.976.796		Nov. 2, 1999	SZALAY et al.	
		US- 6.020.192		Feb. 1, 2000	MUZYCZKA et al.	
		US- 6.025.192		Feb. 15, 2000	BEACH et al.	
		US- 6.025.485		Feb. 15, 2000	KAMB et al.	
		US- 6.027.881		Feb. 22, 2000	PAVLAKIS et al.	
		US- 6.054.321		Apr. 25, 2000	TSIEN et al.	
		US- 6.114.111		Sep. 5, 2000	LUO et al.	
		US- 6.130.313		Oct. 10, 2000	LI et al.	
		US- 6.150.176		Nov. 21, 2000	TSIEN et al.	
		US- 6.197.928		Mar. 6, 2001	TSIEN et al.	
		US- 6.248.550		Jun. 19, 2001	TSIEN et al.	
		US- 6.255.071		Jul. 3, 2001	BEACH et al.	
		US- 6.265.548		Jul. 24, 2001	PAVLAKIS et al.	
		US- 6.316.181		Nov. 13, 2001	FILLMORE et al.	


FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					
		WO 94/19478		Sep. 1, 1994	PEAR et al.		
		WO 97/11094		Mar. 27, 1997	THASTRUP et al.		
		WO 98/14605		Apr. 9, 1998	SZALAY et al.		
		WO 01/32688		May 10, 2001	WARD et al.		
		WO 01/64843		Sep. 7, 2001	FELTS et al.		
		WO 02/057451		Jul. 25, 2002	SORGE et al.		

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard St.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/710,058
		Filing Date	November 10, 2000
		First Named Inventor	ANDERSON, DAVID
		Art Unit	1639
Examiner Name	CELSA, BENNETT M.		
Attorney Docket Number	RIGL-011		
Sheet	2	of	4
OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BORJIGIN, "Insertional mutagenesis as a probe of rhodopsin's topography, stability, and activity," JBC, (1994), 269: 14715-14722	
		CHALFIE, M. et al., "Green fluorescent protein as a marker for gene expression," Science, (1994), 263(5148): 802-5	
		DAY, R.N. et al., "Fluorescence resonance energy transfer microscopy of localized protein interactions in the living cell nucleus," Methods, (2001), 25(1): 4-18	
		DOI et al., "Screening of conformationally constrained random polypeptide libraries," CMLS, (1998), 54(5):394-404	
		FELTS, K. et al., "Recombinant Renilla Reniformis GFP displays low toxicity," Strategies, (2000), 13: 85-87	
		FOSTER, T. P. et al., "Expression of the enhanced green fluorescent protein by herpes simplex virus type 1 (HSV-1) as an in vitro marker for virus entry and replication," J Virol Methods, (1998), 75(2): 151-160	
		GEADA, M.M. et al., "Movement of vaccinia virus intracellular enveloped virions with GFP tagged to the F13L envelope protein," J Gen Virol, (2001), 82(Pt 11): 2747-2760	
		HAWLEY, R.G. et al., "Versatile retroviral vectors for potential use in gene therapy," Gene Ther, (1994), 1(2): 136-8	
		HEIM, R. et al., "Engineering green fluorescent protein for improved brightness, longer wavelengths and fluorescence resonance energy transfer," Curr Biol, (1996), 6(2):	
		KINSELLA, T.M. et al., "Episomal vectors rapidly and stably produce high-titer recombinant retrovirus," Hum Gene Ther, (1996), 7(12): 1405-13	
		KITAMURA T. et al., "Efficient screening of retroviral cDNA expression libraries," Proc Natl Acad Sci, (1995), 92(20): 9146-50	
		LADNER, "Constrained peptides as binding entities," Trends Biotechnol, 1995,13(10):426-30	
		LIU, H.S. et al., "Is green fluorescent protein toxic to the living cells?" (1999), Biochem Biophys Res Commun, 260(3): 712-7	
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard St.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
MAY 28 2003
TECH CENTER 1600/2900



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid PTO control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/710,058		
		Filing Date	November 10, 2000		
		First Named Inventor	ANDERSON, DAVID		
		Group Art Unit	1639		
		Examiner Name	CELSA, BENNETT M.		
Sheet	3	of	4	Attorney Docket Number	RIGL-011

RECEIVED
MAY 28 2003
TECH CENTER 1600/2900


OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		LORENS, J.B. et al., "Retroviral delivery of peptide modulators of cellular functions," Mol Ther, (2000), 1(5): 438-447	
		MAHAJAN, N.P. et al., "Bcl-2 and Bax interactions in mitochondria probed with green fluorescent protein and fluorescence resonance energy transfer," Nat Biotechnol, (1998), 16(6): 547-52	
		MATZ, M.V. et al., "Fluorescent proteins from nonbioluminescent Anthozoa species," Nat Biotechnol, (1999), 17(10): 969-73	
		MCCONNEL et al., "Tendamistat as a scaffold for conformationally constrained phage peptide libraries," J Mol Biol, (1995), 250(4): 460-70	
		MIESENBOCK, G. et al., "Visualizing secretion and synaptic transmission with pH-sensitive green fluorescent proteins," Nature, (1998), 394(6689): 192-5	
		MITRA, R.D. et al., "Fluorescence resonance energy transfer between blue-emitting and red-shifted excitation derivatives of the green fluorescent protein," Gene, (1996), 173(1 Spec No): 13-7	
		MIYAWAKI, A. et al., "Monitoring protein conformations and interactions by fluorescence resonance energy transfer between mutants of green fluorescent protein," Methods Enzymol, (2000), 327: 472-500	
		MIYAWAKI, A. et al., "Fluorescent indicators for Ca ²⁺ -based on green fluorescent proteins and calmodulin, Nature, (1997), 388(6645): 882-7	
		MIYOSHI, H. et al., "Development of a self-inactivating lentivirus vector," J Virol, (1998), 72(10): 8150-7	
		NIWA, H. et al., "Chemical nature of the light emitter of the Aequorea green fluorescent protein," Proc Natl Acad Sci, (1996), 93(24): 13617-22	
		PEAR, W.S. et al., "Production of high-titer helper-free retroviruses by transient transfection," Proc Natl Acad Sci, (1993), 90(18): 8392-6	
		ROGERS, B. et al., "New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter," Strategies, (2000), 13: 141-144	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/710,058
		Filing Date	November 10, 2000
		First Named Inventor	ANDERSON, DAVID
		Group Art Unit	1639
Examiner Name	CELSA, BENNETT M.	Attorney Docket Number	RIGL-011
Sheet	4	of	4

RECEIVED
MAY 28 2003
TECH CENTER 1600/2900

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		ROMOSER, V.A. et al., "Detection in living cells of Ca ²⁺ -dependent changes in the fluorescence emission of an indicator composed of two green fluorescent protein variants linked by a calmodulin-binding sequence. A new class of fluorescent indicators," J Biol Chem, (1997), 272(20): 13270-4	
		SAKAI, R. et al., "Design and characterization of a DNA-encoded, voltage-sensitive fluorescent protein," Eur J. Neurosci, (2001), 13(12): 2314-8	
		SIEGEL, M.S. et al., "A genetically encoded optical probe of membrane voltage," Neuron, (1997), 19(4): 735-41	
		STAUBER, R.H. et al., "Development and applications of enhanced green fluorescent protein mutants," Biotechniques, (1998), 24(3): 462-6, 468-71	
		TSIEN, R.Y., "The green fluorescent protein," Annu Rev Biochem, (1998), 67: 509-44	
		WARD, W.W. et al., "An energy transfer protein in coelenterate bioluminescence. Characterization of the Renilla green-fluorescent protein," J Biol Chem, (1979), 254(3): 781-8	
		YANG, F. et al., "Highly efficient green fluorescent protein-based kinase substrates," Anal Biochem, (1999), 266(2): 167-73	
		ZHENG, C. et al., "Genomic integration and gene expression by a modified adenoviral vector," Nat Biotechnol, (2000), 18(2): 176-80	
		ZOLOTUKHIN, S. et al., "A humanized green fluorescent protein cDNA adapted for high-level expression in mammalian cells," J Virol, (1996), 70(7): 4646-54	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.